- Sant'Anna R.
- Gallego P.
- Robinson L.Z.
- Pereira-Henriques A.
- Ferreira N.
- Pinheiro F.
- Esperante S.
- Pallares I.
- Huertas O.
- Rosario Almeida M.
- Reixach N.
- Insa R.
- Velazquez-Campoy A.
- Reverter D.
- Reig N.
- et al.
Results and discussion
Amyloid fibril preparation

Identification of TTR species in the mechano-enzymatic and ex vivo fibrils
Mechano-enzymatic fibrils | Ex vivo fibrils b Main components of the ex vivo fibrils extracted from a V122I ATTR patient were identified after separation in SDS-PAGE (Fig. S3A) and MALDI-TOF spectra of the fragments eluted from the electrophoretic bands (Fig. S3B). In this sample, the residue 81–127 peptide could not be detected in the material derived from the electrophoretic band, consistent with the apparent size of the fragment. |
---|---|
1-127 | 1-127 |
49-127 | 49-127 |
81-127 | 46-127 |
Stability of V122I TTR precursor and fibrillar structures

Precursor | ΔGH2O | CM |
---|---|---|
V122I TTR | 2.95 ± 0.38 | 0.84 ± 0.06 |
V122I TTR fibrils | ΔG0el | CM |
Low pH | −8.10 ± 0.56 | 0.91 ± 0.16 |
Mechano-enzymatic | −10.61 ± 0.53 | 1.60 ± 0.05 |
Ex vivo | −12.36 ± 1.13 | 1.77 ± 0.20 |

Experimental procedures
Amyloid fibril preparation in vitro
Extraction of natural fibrils ex vivo
Microscopic analysis
Identification of TTR species in the mechano-enzymatic and ex vivo fibrils
Preparation of recombinant V122I TTR
Equilibrium unfolding of native TTR
Depolymerization of TTR fibrils
where MT is the total amount of protein and M is the protein content in the soluble fraction at each denaturant concentration.
Thermodynamic stability parameters of tetrameric TTR
where the yobs is the fluorescence ratio at each denaturant concentration; y0N and y0U are the signals of the native and denaturated states, respectively, in the absence of denaturant; and [D] is the Gdn-SCN concentration. The linear dependence of pre- and post-transition with denaturant concentration is defined by mN and mU, respectively. The model provides quantitative measurements of the difference in free energy between the folded and unfolded state in the absence of denaturant (ΔGH2O), the midpoint denaturant concentration (CM), and the dependence of ΔG on Gdn-SCN (m).
where y is the experimental value observed at a given denaturant concentration, and yN and yU are the values of the native and unfolded protein, respectively, extrapolated from the pre- and post-transition baselines defined by Equation 2 (
Thermodynamic stability parameters of TTR amyloid fibrils
in which [M] and [Fi] represent the concentration of monomers and fibrillar aggregates of size i, respectively, where it is assumed that the equilibrium constants K are equal for all of the interactions between monomers and other species in solutions.
in which ΔGel is the free energy of elongation, R is the gas constant, and T is the absolute temperature. In the presence of chemical denaturants (i.e. Gdn-SCN), ΔGel is linearly dependent on the concentration of denaturant, [D], according to the following,
where m is a cooperativity coefficient and ΔGel0 is the free energy of elongation in the absence of denaturant (
Data availability
Acknowledgments
Supplementary Material
Author Profile
Sara Raimondi
References
- Bioscience—Lost in Translation? How Precision Medicine Closes the Innovation Gap. Oxford University Press, Oxford2016
- Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade.Annu. Rev. Biochem. 2017; 86 (28498720): 27-68
- Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro.Biochemistry. 1992; 31 (1390650): 8654-8660
- Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.JAMA. 2013; 310 (24368466): 2658-2667
- Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.Proc. Natl. Acad. Sci. U. S. A. 2012; 109 (22645360): 9629-9634
- AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.Proc. Natl. Acad. Sci. U. S. A. 2013; 110 (23716704): 9992-9997
- Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity.Nat. Commun. 2016; 7 (26902880): 10787
- Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis.Amyloid. 2013; 20 (23713495): 142-150
- Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis.Proc. Natl. Acad. Sci. U. S. A. 2014; 111 (24474780): 1539-1544
- A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis.EMBO Mol. Med. 2015; 7 (26286619): 1337-1349
- Plasminogen activation triggers transthyretin amyloidogenesis in vitro.J. Biol. Chem. 2018; 293 (30018138): 14192-14199
- Targeting amyloid aggregation: an overview of strategies and mechanisms.Int. J. Mol. Sci. 2018; 19 (30205618): 2677
- Molecular mechanisms of amyloidosis.N. Engl. J. Med. 2003; 349 (12904524): 583-596
- Cryo-EM of amyloid fibrils and cellular aggregates.Curr. Opin. Struct. Biol. 2019; 58 (31200186): 34-42
- Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis.Nat. Commun. 2019; 10 (30894526): 1103
- The characterization of soluble amyloid prepared in water.J. Clin. Invest. 1968; 47 (5641627): 924-933
- A solid sample preparation method that reduces signal suppression effects in the MALDI analysis of peptides.Anal. Chem. 2001; 73 (11217772): 625-631
- Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology.J. Pathol. 2005; 206 (15810051): 224-232
- Trans-suppression of misfolding in an amyloid disease.Science. 2001; 293 (11577236): 2459-2462
- Unfolding free energy changes determined by the linear extrapolation method. 1. Unfolding of phenylmethanesulfonyl α-chymotrypsin using different denaturants.Biochemistry. 1988; 27 (3233195): 8063-8068
- Conformational stability of amyloid fibrils of β2-microglobulin probed by guanidine-hydrochloride-induced unfolding.FEBS Lett. 2004; 576 (15498554): 313-319
- Metastability of native proteins and the phenomenon of amyloid formation.J. Am. Chem. Soc. 2011; 133 (21650202): 14160-14163
- Thermodynamics of amyloid fibril formation from chemical depolymerization.Phys. Chem. Chem. Phys. 2019; 21 (31755512): 26184-26194
- The H50Q mutation induces a tenfold decrease in the solubility of α-synuclein.J. Biol. Chem. 2015; 290 (25505181): 2395-2404
- Co-fibrillogenesis of wild-type and D76N β2-microglobulin: the crucial role of fibrillar seeds.J. Biol. Chem. 2016; 291 (26921323): 9678-9689
- Converging concepts of protein folding in vitroin vivo.Nat. Struct. Mol. Biol. 2009; 16 (19491934): 574-581
- Two decades of progress in structural and dynamic studies of amyloids by solid-state NMR.J. Magn. Reson. 2019; 306 (31311708): 42-47
- Cryo-EM structures of tau filaments from Alzheimer's disease.Nature. 2017; 547 (28678775): 185-190
- Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis.Nat. Commun. 2019; 10 (31676763): 5008
- Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient.Nat. Commun. 2019; 10 (30894521): 1269
- A review of light, polarization and fluorescence microscopic methods for amyloid.Appl. Pathol. 1985; 3 (2429683): 5-17
- Mass spectrometry of whole proteins eluted from sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels.Anal. Biochem. 1997; 247 (9177686): 257-267
- A theory of linear and helical aggregations of macromolecules.J. Mol. Biol. 1962; 4 (14482095): 10-21
Article info
Publication history
Footnotes
This article contains supporting information.
Author contributions—S. R., P. P. M., G. V., D. C., P. N., L. M., R. P., V. M., G. F., G. W. T., J. D. G., A. C., M. B. P., and S. G. investigation; S. R., G. V., D. C., P. N., L. M., V. M., and G. F. methodology; S. R., P. P. M., G. W. T., and M. B. P. writing-review and editing; P. P. M. data curation; G. V. and S. G. formal analysis; S. G. and V. B. supervision; V. B. conceptualization; V. B. writing-original draft.
Funding and additional information—This work was supported by investment from the University College London Technology Fund and United Kingdom Medical Research Council Grant MR/R016984/1 (to V. B.), Rosetrees Trust/Royal Free Charity PhD Programme Grant M427 (to G. V.), Italian Ministry of Health Ricerca Finalizzata RF 2013 02355259 (to V. B.), the Italian Ministry of Research and University Dipartimenti di Eccellenza 2018–2022 grant to the Molecular Medicine Department (University of Pavia), and the Istituto Nazionale di Biostrutture e Biosistemi. Core support for the Wolfson Drug Discovery Unit is provided by the United Kingdom National Institute for Health Research Biomedical Research Centre and Unit Funding Scheme via the UCLH/UCL Biomedical Research Centre and by the UCL Amyloidosis Research Fund.
Conflict of interest—The authors declared that they have no conflict of interest with the contents of this article.
Abbreviations—The abbreviations used are: TTR
Identification
Copyright
User license
Creative Commons Attribution (CC BY 4.0) |
Permitted
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
Elsevier's open access license policy